Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 1/2012

01-02-2012 | Statin Drugs (M Clearfield, Section Editor)

Initiation of Statin Therapy: Are There Age Limits?

Authors: Dipan A. Desai, Sammy Zakaria, Pamela Ouyang

Published in: Current Atherosclerosis Reports | Issue 1/2012

Login to get access

Abstract

Cardiovascular disease (CVD) is the leading cause of death, with a higher prevalence in older adults who form an increasing proportion of the population of the United States. Statin treatment reduces cardiovascular morbidity and mortality in middle-aged adults. However, few studies have included older individuals, particularly ages 80 years or older. We review recent publications regarding primary and secondary prevention of CVD with statin therapy in older adults. Risk scores and their limitations in this population are discussed. The association of adverse effects with intensive doses of statin and their interactions with other drugs may be more problematic in older adults. Statin therapy appears cost-effective for individuals with higher CVD risk but this is dependent on the assumptions used. Evidence remains limited regarding the overall benefit of starting statin therapy in adults ages 80 years and older; thus, clinical judgment remains necessary in making this decision.
Literature
1.
Wald NJ, Simmonds M, Morris JK: Screening for future cardiovascular disease using age alone compared with multiple risk factors and age. PLoS One, 6:e18742.
2.
Committee on the Future Health Care Workforce for Older Americans. Institute of Medicine. Retooling for an Aging America: Building the Health Care Workforce. 2008 August 4, 2008.
3.
Forman DE, Rich MW, Alexander KP, et al. Cardiac care for older adults. Time for a new paradigm. J Am Coll Cardiol. 2011;57:1801–10.PubMedCrossRef
4.
Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.
5.
Holmes MV, Harrison S, Talmud PJ, et al. Utility of genetic determinants of lipids and cardiovascular events in assessing risk. Nat Rev Cardiol. 2011;8:207–21.PubMedCrossRef
6.
LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–6.PubMedCrossRef
7.
Long SB, Blaha MJ, Blumenthal RS, Michos ED. Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly. Clin Interv Aging. 2010;6:27–35.PubMed
8.
Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.PubMedCrossRef
9.
Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007;115:700–7.PubMedCrossRef
10.
Gransbo K, Melander O, Wallentin L, et al. Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J Am Coll Cardiol. 2010;55:1362–9.PubMedCrossRef
11.
Rahilly-Tierney CR, Lawler EV, Scranton RE, Gaziano JM. Cardiovascular benefit of magnitude of low-density lipoprotein cholesterol reduction: a comparison of subgroups by age. Circulation. 2009;120:1491–7.PubMedCrossRef
12.
Lemaitre RN, Psaty BM, Heckbert SR, et al. Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. Arch Intern Med. 2002;162:1395–400.PubMedCrossRef
13.
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22.PubMedCrossRef
14.
Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled tria. Lancet. 2003;361:1149–58.PubMedCrossRef
15.
Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155–63.PubMedCrossRef
16.
Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96.PubMedCrossRef
17.
Neil HA, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65–75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care. 2006;29:2378–84.PubMedCrossRef
18.
Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478–85.PubMedCrossRef
19.
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRef
20.
Koenig W, Ridker PM. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk >/= 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. Eur Heart J. 2011;32:75–83.PubMedCrossRef
21.
• Glynn RJ, Koenig W, Nordestgaard BG, et al.: Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 2010, 152:488–96, W174. This is a retrospective analysis of older patients (aged ≥70 years) in JUPITER to assess whether 20 mg of rosuvastatin is safe and efficacious in reducing cardiovascular events. The older patients had a significant reduction in cardiovascular events without an increase in adverse events. PubMed
22.
Ridker PM, Macfadyen JG, Nordestgaard BG, et al. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5–10% and 10–20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for “intermediate risk”. Circ Cardiovasc Qual Outcomes. 2010;3:447–52.PubMedCrossRef
23.
Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170:1024–31.PubMedCrossRef
24.
Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376–431.PubMedCrossRef
25.
Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.PubMedCrossRef
26.
Rosengren A, Wallentin L, Simoons M, et al. Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. Eur Heart J. 2006;27:789–95.PubMedCrossRef
27.
Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291:1864–70.PubMedCrossRef
28.
Simons LA, Ortiz M, Calcino G. Long term persistence with statin therapy - experience in Australia 2006–2010. Aust Fam Physician. 2011;40:319–22.PubMed
29.
Itakura H, Nakaya N, Kusunoki T, et al. Long-term event monitoring study of fluvastatin in Japanese patients with hypercholesterolemia: Efficacy and incidence of cardiac and other events in elderly patients (>/= 65 years old). J Cardiol. 2010;57:77–88.PubMed
30.
Holbrook A, Wright M, Sung M, et al. Statin-associated rhabdomyolysis: is there a dose–response relationship? Can J Cardiol. 2011;27:146–51.PubMedCrossRef
31.
Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376:1658–69.PubMedCrossRef
32.
Egan A, Colman E: Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med, 365:285–7.
33.
Alexander KP, Blazing MA, Rosenson RS, et al. Management of hyperlipidemia in older adults. J Cardiovasc Pharmacol Ther. 2009;14:49–58.PubMedCrossRef
34.
• Hippisley-Cox J, Coupland C: Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010, 340:c2197. This is a large, prospective cohort study evaluating the benefits and harms of statin therapy that included patients up to age 84 years. Potential outcomes, including effects on cardiac, neurologic, musculoskeletal, renal, hepatic, hematologic, oncologic, ophthalmologic, and rheumatologic organ systems, were evaluated. Statins were associated with a decline in esophageal cancer but increased liver dysfunction, acute renal failure, myopathy, and cataracts.PubMedCrossRef
35.
Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006–16.PubMedCrossRef
36.
Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–64.PubMedCrossRef
37.
Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104:109–24.PubMedCrossRef
38.
• Sattar N, Preiss D, Murray HM, et al.: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735–42. This is a meta-analysis of 13 trials of 91,140 patients evaluating the risk of diabetes with statin therapy. The absolute risk of diabetes due to statin therapy remained low. The study is notable due to the large sample size and the mix of both primary and secondary prevention patients.PubMedCrossRef
39.
Wenger NK, Lewis SJ, Herrington DM, et al. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med. 2007;147:1–9.PubMed
40.
41.
Padala KP, Padala PR, Potter JF. Statins: a case for drug withdrawal in patients with dementia. J Am Geriatr Soc. 2010;58:1214–6.PubMedCrossRef
42.
Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010;170:1648–54.PubMedCrossRef
43.
Jyrkka J, Vartiainen L, Hartikainen S, et al. Increasing use of medicines in elderly persons: a five-year follow-up of the Kuopio 75 + Study. Eur J Clin Pharmacol. 2006;62:151–8.PubMedCrossRef
44.
Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14:447–50.PubMedCrossRef
45.
• Fleg JL, Aronow WS, Frishman WH: Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol 2011, 8:13–28. This is an excellent overview on the treatment of cardiovascular diseases in the elderly, focusing on evidence-based therapies, physiologic alterations in the elderly affecting medication metabolism and efficacy, and polypharmacy issues.PubMedCrossRef
46.
Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother. 2004;38:978–81.PubMedCrossRef
47.
Enger C, Gately R, Ming EE, et al. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am J Cardiol. 2010;106:1594–601.PubMedCrossRef
48.
Sirtori CR, Mombelli G, Triolo M, Laaksonen R: Clinical response to statins: Mechanism(s) of variable activity and adverse effects. Ann Med 2011.
49.
Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.PubMed
50.
D’Agostino Sr RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–53.PubMedCrossRef
51.
Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611–9.PubMedCrossRef
52.
Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293–304.PubMedCrossRef
53.
Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118:2243–51.PubMedCrossRef
54.
Foody JM, Krumholz HM. Are statins indicated for the primary prevention of CAD in octogenarians? antagonist viewpoint. Am J Geriatr Cardiol. 2003;12:357–60.PubMedCrossRef
55.
Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA. 1994;272:1335–40.PubMedCrossRef
56.
Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829–39.PubMedCrossRef
57.
Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335:136.PubMedCrossRef
58.
Hippisley-Cox J, Coupland C, Robson J, Brindle P. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ. 2010;341:c6624.PubMedCrossRef
59.
Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet. 1995;346:1467–71.PubMedCrossRef
60.
• Weatherley ND, Jackson PR: The new Sheffield risk and benefit tables for the elderly. QJM 2011, 104:3–12. The new Sheffield table evaluates the risk and benefit of blood pressure control and statin therapy in individuals older than 75 years. This article provides gender-specific tables to predict the potential gain from taking antihypertensive medication or a statin for a combination of age and risk factor score.PubMedCrossRef
61.
Simons LA, Simons J, Friedlander Y, et al. Risk functions for prediction of cardiovascular disease in elderly Australians: the Dubbo Study. Med J Aust. 2003;178:113–6.PubMed
62.
Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010;303:1610–6.PubMedCrossRef
63.
Paramsothy P, Katz R, Owens DS, et al. Age-modification of lipoprotein, lipid, and lipoprotein ratio-associated risk for coronary artery calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol. 2010;105:352–8.PubMedCrossRef
64.
Choudhry NK, Patrick AR, Glynn RJ, Avorn J. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. J Am Coll Cardiol. 2011;57:784–91.PubMedCrossRef
65.
• Greving JP, Visseren FL, de Wit GA, Algra A: Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ 2011, 342:d1672. This is a cost-effectiveness analysis of low-dose statins in men and women aged 45 to 75 years without vascular disease at different degrees of risk for vascular disease using real-world cost and nonadherence estimates. The treatment effect of statins on reducing CVD was obtained from a recent meta-analysis of 10 randomized, controlled primary prevention statin trials. This trial demonstrated that a low-dose statin at low vascular disease was not cost-effective, but as the vascular risk increased so did the cost-effectiveness of low-dose statin.PubMedCrossRef
Metadata
Title
Initiation of Statin Therapy: Are There Age Limits?
Authors
Dipan A. Desai
Sammy Zakaria
Pamela Ouyang
Publication date
01-02-2012
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 1/2012
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-011-0220-1

Other articles of this Issue 1/2012

Current Atherosclerosis Reports 1/2012 Go to the issue

Nonstatin Drugs (W Borden, Section Editor)

New Horizons for Cholesterol Ester Transfer Protein Inhibitors

Statin Drugs (M Clearfield, Section Editor)

Role of C-Reactive Protein When Prescribing a Statin

Nonstatin Drugs (W Borden, Section Editor)

Novel Antiplatelet Therapies

Statin Drugs (M Clearfield, Section Editor)

A Review of the Rationale for Additional Therapeutic Interventions to Attain Lower LDL-C When Statin Therapy Is Not Enough

Nonstatin Drugs (W Borden, Section Editor)

Niacin: The Evidence, Clinical Use, and Future Directions

Nonstatin Drugs (W Borden, Section Editor)

Lipid Effects of Antihypertensive Medications
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits